Cidofovir: Difference between revisions
From IDWiki
No edit summary |
No edit summary |
||
Line 1: | Line 1: | ||
+ | == Background == |
||
⚫ | |||
+ | |||
⚫ | |||
⚫ | |||
⚫ | |||
+ | |||
+ | === Spectrum of Activity === |
||
+ | |||
+ | * Active against essentially all DNA viruses, including polyomaviruses ([[BK virus]], [[JC virus]]), [[human papillomavirus]], [[adenovirus]], all of the [[human herpesviruses]], poxviruses (including [[monkeypox virus]] and [[variola virus]]) |
||
+ | * Not active against h[[Hepatitis B virus|epatitis B virus]] or [[:Category:RNA viruses|RNA viruses]] |
||
+ | |||
+ | === Pharmacokinetics and Pharmacodynamics === |
||
+ | |||
* Unlike [[ganciclovir]], it does ''not'' need phosphorylation by UL97 |
* Unlike [[ganciclovir]], it does ''not'' need phosphorylation by UL97 |
||
+ | |||
⚫ | |||
+ | == Dosing == |
||
⚫ | |||
+ | |||
⚫ | |||
+ | |||
+ | == Safety == |
||
+ | |||
⚫ | |||
[[Category:Antivirals]] |
[[Category:Antivirals]] |
Revision as of 13:54, 11 September 2020
Background
- Cytosine nucleotide analogue that inhibits DNA polymerase in human herpesviruses
- Indications: Adenovirus, CMV after solid organ transplantation, Cytomegalovirus, Herpes simplex virus
Spectrum of Activity
- Active against essentially all DNA viruses, including polyomaviruses (BK virus, JC virus), human papillomavirus, adenovirus, all of the human herpesviruses, poxviruses (including monkeypox virus and variola virus)
- Not active against hepatitis B virus or RNA viruses
Pharmacokinetics and Pharmacodynamics
- Unlike ganciclovir, it does not need phosphorylation by UL97
Dosing
- Should be given with probenecid 2 g IV prior to each dose
Safety
- Major adverse effect is irreversible renal tubular necrosis, which may be prevented by probenecid